What side effects are associated with this type of intervention?

Common treatments for liver cirrhosis, particularly those involving statins like simvastatin, are generally well-tolerated but can have side effects. These may include muscle pain or weakness (myopathy), liver enzyme abnormalities (transaminitis), and, in rare cases, more severe liver damage. Other potential side effects include gastrointestinal issues such as nausea and constipation, as well as an increased risk of diabetes. It is important for patients to be monitored regularly by their healthcare provider to manage and mitigate these risks.

What prior FDA approvals exist?

The FDA has not specifically approved statins like simvastatin for the treatment of liver cirrhosis. However, statins have been studied for their potential benefits in patients with liver conditions, including cirrhosis. Simvastatin, an HMG-CoA reductase inhibitor, is being investigated in clinical trials for its ability to lower the risk of hepatic decompensation in patients with compensated cirrhosis. Other statins, such as atorvastatin, have also been explored for their effects on liver disease, but their primary FDA approval remains for managing dyslipidemia and cardiovascular risk.

What other types of research exist?

Promising alternatives to Simvastatin for liver cirrhosis patients include PCSK9 inhibitors such as alirocumab and evolocumab, as well as inclisiran. These drugs effectively lower LDL-C and have been shown to be safe in patients with mild to moderate hepatic impairment.

← Back to Search

Statin

Simvastatin for Liver Cirrhosis (SACRED Trial)

Phase 3

Waitlist Available

Led By David E. Kaplan, MD MSc

Research Sponsored by VA Office of Research and Development

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

High risk of cirrhosis decompensation as defined by specific criteria

Cirrhosis due to chronic viral hepatitis, alcohol, or non-alcoholic fatty liver

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 months

Awards & highlights

SACRED Trial Summary

This trial will test whether simvastatin can lower the risk of hepatic decompensation in people with compensated cirrhosis. It will also explore how changes in genes effect the safety and effectiveness of using statins and how the use of statins affects quality of life.

Who is the study for?

This trial is for U.S. Veterans aged 18-80 with compensated cirrhosis, indicated by specific liver conditions and test results. Participants must not have had certain complications like overt ascites or hepatic encephalopathy recently, no history of hepatocellular carcinoma, and should not be on conflicting medications or have other severe health issues.Check my eligibility

What is being tested?

The study tests if Simvastatin (40mg), a drug normally used to lower cholesterol, can prevent worsening symptoms in patients with high-risk compensated cirrhosis compared to a placebo. It's randomized and double-blind, meaning neither the researchers nor participants know who gets the real medicine.See study design

What are the potential side effects?

Simvastatin may cause muscle pain or weakness, liver enzyme changes leading to potential liver damage, digestive problems like constipation or nausea, increased blood sugar levels which could lead to diabetes risk increase.

SACRED Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am at high risk for my liver condition getting worse.

Select...

I have cirrhosis caused by hepatitis, alcohol, or fatty liver disease.

Select...

My liver disease is stable with specific health criteria met.

Select...

I understand and can agree to the study's procedures and risks.

Select...

I am between 18 and 80 years old.

SACRED Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Survival free from hepatic decompensation

Secondary outcome measures

Change in patient health-related quality of life

Hepatotoxicity

Liver-related death

+4 more

SACRED Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: SimvastatinExperimental Treatment1 Intervention

Simvastatin 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.

Group II: PlaceboPlacebo Group1 Intervention

Placebo 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Simvastatin 40mg

2018

Completed Phase 2

~160

0 / 5Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Statins, such as simvastatin, are commonly used in the treatment of liver cirrhosis due to their ability to inhibit HMG-CoA reductase, an enzyme crucial for cholesterol synthesis. By lowering cholesterol levels, statins help reduce liver inflammation and fibrosis, which are key factors in the progression of cirrhosis. Moreover, statins have been associated with a decreased risk of hepatic decompensation and hepatocellular carcinoma, making them valuable in improving liver function and reducing complications in cirrhosis patients.

SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation.An Evidence-Based Review of Statin Use in Patients With Nonalcoholic Fatty Liver Disease.